106 results about "Placental disc" patented technology

Cells derived from postpartum tissue such as the umbilical cord and placenta, and methods for their use to regenerate, repair, and improve neural tissue, and to improve behavior and neurological function in stroke patients are disclosed.

A placental tissue assembly for treating wounds or surfaces of a patient has one or more layers of placental tissue and a backing material. The one or more layers of placental tissue have a first side and a second side. The backing material is adhered to and covers one of either the first or second sides of the one or more layers of placental tissue to create the assembly. The assembly when applied onto a surface to be treated on the side of the tissue opposite the backing material adheres to the surface with an attachment force greater than an attachment force of the backing material adhered to the first or second side. This allows the backing material to be released leaving the placental tissue affixed to the surface to be treated.

The invention discloses four cell types which have wide heteroplastic transplantation application prospect and can be effectively induced into induced pluripotent stem (iPS) cells. The origins of three cell types are placental tissue, namely amnion mesenchymal cell, chorion mesenchymal cell and umbilical cord mesenchymal cell; and the origin of the other one is amniotic fluid cell. Besides, the invention also discloses an induction reprogramming method for producing cells capable of producing induced pluripotent stem (iPS) cells by efficient induction, including the following steps: cDNA containing pluripotent stem cell factor is respectively introduced into the four primary culture cells; the four primary cells in which cDNA is introduced are respectively cultured on appropriate culture mediums, primary iPS is obtained and then quality of iPS is optimized on appropriate culture mediums, and cloning of pluripotent stem cell can be primarily evaluated. In the invention, three mesenchymal cells of placenta origin and amniotic fluid cell all can be induced into iPS, wherein the chorion mesenchymal cell is compared with fibroblast, efficiency of induction reprogramming is improved by over 100 times, efficiency is about 2.3%, and the efficiency is slightly higher than that of horny cell; and a means which is more effective and more pertinent is provided for building disease model, screening drug and controlling oriented differentiation.

A tissue engineering cartilage based on placenta original filled stem cell and its production are disclosed. The process is carried out by constructing bony tissue from composite biological brace material of placenta original filled stem cell. It can be used to repair bony injure and bony tissue deficit.

Compositions of matter, of production, and treatment modalities are disclosed for the prevention and/or therapeutic reduction of tumors through induction of immunity against tumor associated fibroblasts and components of tumor microenvironment. In one embodiment of the invention, placentally derived fibroblast cells are cultured under conditions replicating tumor microenvironment. Expression of CD248 on said cultured fibroblasts is used as a marker of effective manipulation. Cells expressing CD248 are utilized a immunogens for stimulation of immunity towards cancer associated fibroblastic cells.

The invention relates to a preparation method of placental-chorionic-plate-tissue-derived mesenchymal stem cells, and belongs to the technical field of cell biology. The preparation method of the placental-chorionic-plate-tissue-derived mesenchymal stem cells comprises the following steps: carrying out tissue separation, namely to obtain a placenta tissue sample, separate out chorion tissue, and carry out washing with a tissue cleaning solution until the chorion tissue is semi-translucent; carrying out tissue cryopreservation, namely to put the washed chorion tissue into a cryopreservation solution, and carry out cooling and cryopreservation according to predetermined procedures; carrying out tissue treatment, namely to take out the chorion tissue after the cryopreservation, soak the chorion tissue with ethanol, remove impurities, and perform shearing so as to obtain tissue masses; and then, carrying out cell culture, namely to put the tissue masses into a culture flask, add a mesenchymal stem cell selection medium so as to obtain a mixture, put the mixture into a CO(2) incubator so as to carry out incubation until cell fusion degree reaches 80+/-10%, carry out cell passage, and continue amplification culture and/or cryopreservation of the passage cells. The preparation method of the placental-chorionic-plate-tissue-derived mesenchymal stem cells enables long-term storage of placental chorionic plate tissue and mesenchymal stem cells separated from the placental-chorionic plate tissue in liquid nitrogen; and moreover, the placental chorionic plate tissue and the mesenchymalstem cells still have maintained cell activity after reconstruction.

Disclosed are means of inducing neuroregeneration and/or neuroprotection in patients with damage to the nervous system. In one embodiment, placenta derived CD34 positive cells are administered to a patient suffering from a neurological injury, said cells administered alone, or in combination with endothelial progenitor cells that are derived from placental sources. In one embodiment cells are manipulated to decrease immunogenicity by means of gene-editing or RNA interference inducing means. In another embodiment, neuroprotection and/or neuroregeneration is achieved by administration of exosomes derived from placental stem cells.

The invention relates to a video image reorganization processing method. The method comprises the steps that data collection of placenta position, placenta thickness, retroplacental low echo zone, glandulae vesicales, placenta lacuna, placenta basilar part blood flow, one or more cervix uteri blood sinus, cervix uteri shape and cesarean section history is conducted. In addition, the invention further relates to a video data processing module and a device using the processing module.

The present invention relates to a human amniotic epithelial cell separation method, which comprises: 1, collecting and transporting placenta; 2, tearing and taking the amnion; 3, rinsing the amnion; 4, cutting the amnion; 5, digesting the amnion epithelium surface; 6, terminating the digestion; 7, collecting cells through centrifugation; and 8, resuspending the amniotic epithelial cells, and carrying out inoculating culture. According to the present invention, the high purity amniotic epithelial cells can be separated, the number of the cells is more, the cell activity is high, and the basis is established for the research and the clinical applications of the amniotic epithelial cells.

The present disclosure provides compositions composed of amniotic fluid and/or modified amniotic fluid, a pharmaceutically acceptable carrier, and optionally a placental tissue graft, micronized placental tissue components, or extracts derived therefrom. Also described are systems and apparatuses for administering or storing said compositions, as well as methods of treatment using said compositions.

The invention discloses placental villus plate mesenchymal stem cells. A clinical preparation method of the placental villus plate mesenchymal stem cells comprises the following steps: (1) acquiring a placental villus plate; (2) removing blood vessels and villus tissues; (3) cleaning the placental villus plate by virtue of sterile physiological saline until the placental villus plate has no blood color; (4) cutting villus plate tissues into 1-5mm[2], and cleaning the cut villus plate tissues by virtue of physiological saline; (5) inoculating tissue blocks into a complete medium, and cultivating the tissue blocks in a moist incubator which is at 37 DEG C and contains 5% of CO2; (6) changing the medium once every 6-11 days, and digesting the cells by virtue of TrypLE<TM> Select when a cell fusion degree is 70-80%; (7) conducting subculture; (8) conducting detection; (9) conducting cryopreservation; and (10) building a data base. According to the clinical preparation method disclosed by the invention, the placental villus plate is taken as a material, such operations as sorting, soaking, filtration and gradient centrifugation are not needed in an extracting process, so that many cells can be obtained by a relatively few of generation times; therefore, cost consumption and separation time can be greatly reduced, and the yield and purity of the mesenchymal stem cells can be improved.

The present invention belongs to the field of medical teaching tools, and relates to a teaching model based on an antenatal diagnosis puncture technology and an application method thereof. The teaching model based on the antenatal diagnosis puncture technology comprises a model main body, an assembling mechanism and an observation mechanism; and the model main body comprises a uterus model body, asupport, a lower abdomen model body, an upper abdomen model body, an umbilical cord model body and a placenta model body. When practicers perform simulation training, model images in the observationmechanism are employed to perform puncture operation, when puncture needles contact a mini acupuncture sensor arranged at the target puncture position of the model, the mini acupuncture sensor immediately emits alarm prompting signals to inform the practicers of completion of the puncture operation, the practicers establish space correspondence of two-dimensional images in a visual mirror and a three-dimensional entity of a puncture model through repeat training so as to improve the puncture operation accuracy and stability.

The present invention discloses the preparation of placenta tissue derived CD106^high CD151+Nestin+ mesenchymal stem cells (MSCs). In a first aspect, the invention relates to a particular method to prepare these cells at industrial scale and the cell population generated thereby. In a second aspect, the invention relates to a cell culture obtained by said particular method, containing placental CD106^high CD151+Nestin+ MSCs expressing the vascular cell adhesion molecule 1 (VCAM-1) marker. The present application shows that said placental CD106^high CD151+Nestin+ MSCs are capable of inducing angiogenesis in vitro and in vivo. The herein presented results also show that administering said placental CD106^high CD151+Nestin+ MSCs to individuals suffering from an ischemic disease or from a disorder of the circulatory system results in a detectable improvement of one or more symptoms of said disease or disorder. Therefore, in a third aspect, the invention relates to placental CD 106^high CD151+Nestin+ MSCs for use as a medicament for treating subjects suffering from an ischemic disease, a disorder of the circulatory system, an immune disease, an organ injury or an organ function failure.

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer (PINK) cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. In a preferred embodiment, the composition comprises: solated CD56+, CD16- natural killer cells.

The invention provides a method for diagnosing whether a subject has preeclampsia or is at the risk of preeclampsia, and further provides application of microRNA and/or a specific probe/detection primer of the microRNA in preparation of a diagnostic composition and the diagnostic composition for detecting preeclampsia. The expression of the microRNA 27a in the plasma in a preeclampsia patient is obviously reduced, and the microRNA 27a can be used as a diagnostic index which is valuable, simple, convenient and easy to dynamically monitor preeclampsia; and meanwhile, the reduction of the microRNA 27a in the placenta tissue is further a potential diagnostic index for predicting preeclampsia.